AIM Stockholder Full Value Committee Reiterates Intent to Proceed with Nominations and Proxy Solicitation
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Jonathan Jorgl, an AIM ImmunoTech Inc. (NYSE American: AIM), (“AIM”) stockholder, together with his nominees, Robert L. Chioini and Michael Rice (collectively, the “AIM Stockholder Full Value Committee” or the “ASFV Committee”), today reiterated their commitment to proceed with the solicitation of proxies for the election of Mr. Chioini and Mr. Rice to the AIM board of directors at the upcoming 2022 annual meeting.
- Therefore, AIM is prevented from proceeding with the annual meeting and blocking the nominations of Mr. Chioini and Mr. Rice prior to a court ruling.
- THE ASFV COMMITTEE STRONGLY ADVISES ALL STOCKHOLDERS OF AIM TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
- IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.
- The participants in the proxy solicitation are expected each to be member of the ASFV Committee and River Rock Advisors LLC (collectively, the Participants).